Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the impact of AbbVie Care 2.0 on adalimumab's compliance, patient reported outcomes and utilization of health resources over 12 months.

Official Title
-----------------
Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal

Conditions
-----------------
Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis (AS), Non-radiographic Axial Spondyloarthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with crohn's disease (CD), ulcerative colitis (UC), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (SpA) or psoriasis (Pso) according to the treating physician Adalimumab was started within 1 month prior to study enrollment Adalimumab was introduced based on current clinical practice criteria (i.e., the prescription of adalimumab was clearly separated from the decision to include the participants in this study) No prior record of adalimumab treatment Adalimumab was administered according to product label Naïve or previously experienced with biologic treatment Participant is able and willing to provide written authorization to disclose and use personal health information (informed consent), and to agree that data will be collected and provided to AbbVie AbbVie Care 2.0 Cohort-specific inclusion criteria: Initiated the AbbVie care program within the first month after starting adalimumab. Exclusion Criteria: Definitive discontinuation of adalimumab before being proposed to participate in the study Participated in any clinical experimental research within the 2 months prior to enrollment Pregnant or breastfeeding female participants Participant not able or not willing to comply with the requirements of this study protocol.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants not included in the AbbVie care program<br>Participants receiving adalimumab not included in the AbbVie care patient support program. | |
| Participants included in the AbbVie care program<br>Participants receiving adalimumab included in the AbbVie care patient support program. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with Medication Possession Ratio (MPR)>=80% | The variable MPR will be used, considering in the numerator the sum of days supply between start of observation (baseline) and last prescription dispensed (including the days of last prescription) and as denominator the number of days elapsed between baseline and last prescription dispensed (including the days of last prescription). | Up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean number of injections administered/ prescribed for adalimumab | This is assessed based on patient diary. | Up to 12 months | 
| Assessing Patient's overall satisfaction with AbbVie Care 2.0 program | Patient's overall satisfaction with AbbVie Care 2.0 program is scored at 1: Very good, 2: Good and 3: Less satisfying. | At 12 months | 
| Number of Sick Leaves | This is assessed by reviewing work time lost due to other reasons than health problems during previous last seven days. | Up to 12 months | 
| Time Spent by the Patient to Refill Prescription | This is assessed by reviewing the work productivity indicator over 12 months. | Up to 12 months | 
| Number of Hospital Inpatient Days | This is assessed by reviewing the use of health resources over 12 months. | Up to 12 months | 
| Number of Emergency Visits | This is assessed by reviewing the use of health resources over 12 months. | Up to 12 months | 
| Assessing Working Status | This is assessed by the proportion of patients employed. | Up to 12 months | 
| Proportion of patients with MPR>=80% | The variable MPR will be used, considering in the numerator the sum of days supply between start of observation (baseline) and last prescription dispensed (including the days of last prescription) and as denominator the number of days elapsed between baseline and last prescription dispensed (including the days of last prescription). | At Month 6 | 
| Mean score of Treatment Satisfaction Questionnaire for Medication (TSQM)-II | This 14-point measure attempts to show that adherence is expected to be related with patients' satisfaction with therapy and such satisfaction can be a function of not only the effect of the treatment, but also the services offered. Domains include: Effectiveness, Side effects, Convenience and Global satisfaction. | Up to Month 12 | 
| Mean Change in EuroQoL (EQ-5D) score | EQ-5D considers five attributes of quality of life evaluation, i.e., mobility, self-care, usual activity, pain/ discomfort, and anxiety/ depression. | From Month 0 to Month 12 | 
| Number of Complementary Exams/ Techniques | This is assessed by reviewing the use of health resources over 12 months. | Up to 12 months | 
| Number of Hospitalizations | This is assessed by reviewing the use of health resources over 12 months. | Up to 12 months | 
| Time Spent by the Health Care Providers (HCPs) During Medical Appointments | This is assessed by reviewing the use of health resources over 12 months. | Up to 12 months | 
| Mean Change in Patient Activation Measure (PAM-13) | This is a powerful and reliable measure of patient activation. It is 13-item measure used to assess the patient knowledge, skill, and confidence for self-management. | From Month 0 to Month 12 | 
| Mean Change in Beliefs about Medication Questionnaire (BMQ) | The BMQ comprises two sections: the BMQ-Specific, which assesses representations of medication prescribed for personal use and the BMQ-General, which assesses beliefs about medicines in general. This questionnaire is validated for use in Portugal. | From Month 0 to Month 12 | 
| Change in Work Productivity and Activity Impairment- General Health (WPAI-GH) | WPA-GH assesses the impact of general health problem on work productivity and daily activities during the previous 7 days. | From Month 0 to Month 12 | 
| Number of Outpatient Visits (in-office and remote) in Hospital Setting | This is assessed by reviewing the use of health resources over 12 months. | Up to 12 months | 
| Number of Days of Sick Leaves | This is assessed by reviewing work time lost due to health problems during previous seven days. | Up to 12 months | 
| Proportion of patients who are still on adalimumab after 6 and 12 months | This is used to assess persistence and it could be done using pharmacy refills. | Up to 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adalimumab, Humira®, AbbVie patient care support program, Psoriasis, Axial Spondyloarthritis, Rheumatoid Arthritis, Ulcerative Colitis